This engineered antibody (a-CTLA4TGFβRIIecd and a-PDL1-TGFβRIIecd) significantly counteracted Tregs and restored beneficial TH1 cells in the TME, exhibiting superior antitumor efficacy than either the CTLA-4 antibody or PD-L1 antibodies in human melanoma (A375)–bearing NSG mice (156). The gene discussed is CD274; the disease is melanoma.